Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a U.S.-based biotechnology company focused on discovering and developing therapies for central nervous system and other serious diseases. Its portfolio includes clinical-stage and discovery-stage programs, with operations conducted through a group of U.S., Australian, Portuguese, and former U.K. subsidiaries.

11.35

11.35

— Pasithea Therapeutics Corp.
%
Clinical-stage drug programs0% Therapeutic candidates being advanced through clinical development and regulatory review.
Discovery-stage programs0% Early-stage research programs aimed at identifying new drug candidates for CNS diseases.
Preclinical research and development0% Laboratory and translational work supporting target validation and candidate selection.
Corporate and development operations100% Internal functions supporting financing, IP, and advancement of the pipeline.

Pasithea does not appear to sell commercial products yet; its primary stakeholders are regulators, clinical...

  • ALS patients and treating cliniciansemerging

    Future users of PAS-003 if development succeeds; the program targets unmet need in amyotrophic lateral sclerosis.

  • Schizophrenia patients and psychiatristsemerging

    Future users of PAS-001 if it advances successfully; the program is aimed at a major CNS indication.

  • Clinical research ecosystemprimary

    Trial sites, investigators, CROs, and regulators that support preclinical and clinical advancement.

  • Capital providers and strategic partnersprimary

    Equity, debt, and collaboration counterparties that fund development and extend operating runway.

Pasithea is headquartered in the United States and operates through subsidiaries in the U.S...

  • •Headquartered in the United States
  • •Subsidiaries include Delaware entities and an Australian company
  • •Former U.K. and Portugal operations have been discontinued
  • •Geography matters mainly for R&D execution and corporate structure
  • •No disclosed country revenue mix because the company is pre-commercial

Pasithea’s strategy is to advance its pipeline through discovery, preclinical work, and clinical development while...

01
Advance lead and discovery programsshort-term

Pipeline progression is the main value driver for a pre-commercial biotech.

02
Raise external capitalshort-term

Development programs require funding before any product revenue exists.

03
Protect and expand intellectual propertymedium-term

IP underpins exclusivity and future partnering or commercialization value.

Pasithea faces the typical risks of a pre-revenue biotech: clinical failure, regulatory delay, and the possibility that...

critical

Pipeline development failure

Drug candidates may not show sufficient safety or efficacy in preclinical or clinical testing.

Scope
PAS-004, PAS-003, PAS-001
Materiality
high
critical

Financing shortfall

The company expects to need additional capital before it can fund development and operations.

Scope
Equity, debt, ATM, shelf offerings
Materiality
high
high

Nasdaq listing compliance

Failure to maintain bid-price and other listing requirements could trigger delisting.

Scope
Common stock and public warrants
Materiality
high
medium

Competitive therapeutic landscape

Other approved or emerging therapies could limit market opportunity for its candidates.

Scope
ALS and schizophrenia programs
Materiality
medium
Research and development expense
Affects operating loss and cash burn
Stock-based compensation
Can materially increase reported expenses
Fair value measurements
Affects net income volatility
Going-concern assessment
Important for solvency and disclosure analysis

PROTHENA CORP PUBLIC LTD CO

PRTA · Pharmaceutical Preparations

Lantheus Holdings, Inc.

LNTH · In Vitro & In Vivo Diagnostic Substances

Vistagen Therapeutics, Inc.

VTGN · Pharmaceutical Preparations

Protagonist Therapeutics, Inc

PTGX · Pharmaceutical Preparations

LISATA THERAPEUTICS, INC.

LSTA · Pharmaceutical Preparations

VERTEX PHARMACEUTICALS INC / MA

VRTX · Pharmaceutical Preparations

: 29.4.2026